Contents
A review by four immunologists at St. Jude Children’s Research Hospital, published in Cell Research on Sept. 4, 2026, explains how innate immune sensors assemble into inflammasomes and PANoptosomes, the protein complexes that set off inflammation and inflammatory cell death. Its main conclusions are that cryo-electron microscopy has shown how several sensors switch from a resting to an active form, that most drug candidates so far target a single sensor, NLRP3, and that no complete structure of an assembled inflammasome or PANoptosome has yet been solved.
The researchers Saurabh Upadhyay, Raghavendra Nagampalli, Sara Resende along with Thirumala-Devi Kanneganti review existing studies instead of detailing a novel trial, and the publication is made available with open access.
What inflammasomes and PANoptosomes are
Inflammasomes function as protein assemblies responsible for triggering the enzyme caspase-1. Subsequently, caspase-1 processes a pair of inflammatory signaling molecules, namely IL-1β and IL-18, while simultaneously cleaving the gasdermin D protein to generate membrane pores within the cell.
PANoptosomes drive PANoptosis, an inflammatory form of cell death that combines features of pyroptosis, apoptosis and necroptosis. Inflammasomes can be part of them, and they also release other signals such as TNF and interferons. The sensors the review places in PANoptosomes include ZBP1, AIM2, RIPK1, NLRP3, NLRP1, NLRC5 and NLRP12.
How the main sensors switch on
NLRP3 remains confined within a cage-shaped assembly until the NEK7 protein attaches to it. Subsequently, it reshapes into a disk-like structure that extends filaments to gather the ASC adaptor protein. Conversely, AIM2 becomes active upon recognizing double-stranded DNA, a process that alleviates its autoinhibition.
| Sensor | What activates or restrains it | Conditions the review links to it |
|---|---|---|
| NLRP3 | Triggered following NEK7 binding | Cryopyrin-associated periodic syndromes (CAPS); Alzheimer’s and Parkinson’s disease |
| NLRP1 | Suppressed by DPP9 until a detached fragment builds filaments | Skin and autoimmune conditions; traumatic brain injury |
| NAIP/NLRC4 | NAIP recognizes bacterial molecules like flagellin to oligomerize NLRC4 | Enterocolitis caused by gain-of-function mutations |
| Pyrin | Its triggering relies on phosphorylation controlled by Rho GTPases alongside 14-3-3 proteins | Familial Mediterranean fever (FMF) |
The evaluation additionally links such pathways to infections—which they assist in combating and pathogens attempt to thwart—as well as to obesity, diabetes, gout, along with cardiovascular and renal disorders. Regarding malignancies, their function varies according to the circumstances, with research documenting both tumorigenic and tumor-inhibiting impacts.
Where drug development stands
Most candidates target NLRP3. MCC950, the best-known inhibitor, holds the sensor in its inactive shape, but its clinical development has been limited by off-target toxicity and by its failure to block some CAPS-causing variants. Other NLRP3 agents include CY-09, dapansutrile (OLT1177) and molecules that degrade NEK7, and the review notes that some have reached clinical evaluation.
Further along the route, the evaluation addresses the inhibition of caspase-1 alongside gasdermin D. Regarding FMF, colchicine continues to be the most frequently prescribed therapy, despite lacking specific activity against Pyrin. The researchers propose that focusing on distinct sensors—rather than common components like ASC or caspase-1—might enhance therapeutic precision, while identifying IL-1β, IL-18, C-reactive protein, and ferritin as potential indicators of pathological activity.
What remains unknown
To this day, an atomic-resolution structure for a completely assembled inflammasome or PANoptosome remains elusive, leaving many suggested PANoptosome models derived strictly from imaging, biochemical, and genetic insights. Both NLRC5 and NLRP12 are characterized solely at the individual domain level, while the complete architecture of Pyrin continues to be unknown. Furthermore, the majority of structural investigations have relied on a single trigger, failing to capture the physiological reality of the human body, where multiple signals frequently converge simultaneously.
References
- Upadhyay S., Nagampalli R., Resende S. and Kanneganti T.-D., “Innate immune sensors of inflammasomes and PANoptosomes: structural–mechanistic insights and therapeutic implications”, Cell Research, vol. 36, pp. 747–768, published Sept. 4, 2026. Open-access full text on PubMed Central.
